Cash burn in the last financial year was ~$4.15m, suggestive of a 3.5 year cash runway, but costs will only increase as the company approaches and enters clinical trials in its CAR-T program.
Chimeric is currently in Phase 1 for its lead CAR-T therapy– its cash burn for the last half was ~$7m.
Another company in which I’m invested, PYC Therapeutics, is aiming to complete pre-clinical and commence Phase 1 on its lead program later this year. It's working through manufacturing, toxicology etc. at the moment. The last half year (H1 2022) R & D and corporate and admin spend was ~ $12.5m, up ~$5m on H1 2021 as the company works to complete the requirements for submission of an IND to commence Phase 1.
So, while I recognize that SYC is prudent in managing the company’s cash, I cannot see a cash burn of just $4m p.a. being sustained.
PTX Media related, page-334
-
- There are more pages in this discussion • 1,284 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.0¢ |
Change
-0.001(2.44%) |
Mkt cap ! $32.21M | |||
| Open | High | Low | Value | Volume |
| 4.1¢ | 4.3¢ | 4.0¢ | $32.76K | 778.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 1305968 | 4.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 596321 | 1 |
View Market Depth
| Last trade - 15.59pm 13/11/2024 (20 minute delay) ? |
| PTX (ASX) Chart |